

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

CHANGE OF JOINT COMPANY SECRETARY AND AGENT FOR ACCEPTING SERVICE OF PROCESS AND NOTICES IN HONG KONG

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd. (the “**Company**”) announces that Dr. Liu Wei (“**Dr. Liu**”) ceased to be the joint company secretary of the Company with effect from 27 April 2021 due to his retirement.

The Board also announces that Mr. Chan Sing Yuen, Roy (“**Mr. Chan**”) has been appointed as the new joint company secretary of the Company from 27 April 2021. Accordingly, the current joint company secretaries of the Company are Mr. Wu Yijian (“**Mr. Wu**”) and Mr. Chan.

Reference is made to a waiver (the “**Waiver**”) granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with the relevant requirements of Rule 3.28 and Rule 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) for a period of three years commencing from the date of appointment of Mr. Wu as a joint company secretary of the Company (i.e. 28 December 2018), on the condition that Dr. Liu would assist Mr. Wu to discharge the duty as a joint company secretary during the waiver period.

The Stock Exchange has granted a new waiver (the “**New Waiver**”) to the Company from strict compliance with the relevant requirements of Rule 3.28 and Rule 8.17 of the Listing Rules for the remaining period of the Waiver (i.e. from 27 April 2021 to 27 December 2021) (“**Remaining Period**”), on the condition that Mr. Chan will assist Mr. Wu to discharge the duty as a joint company secretary during the Remaining Period, and that the New Waiver could be revoked if there is any material breach of the Listing Rules by the Company. The Stock Exchange expects that before the end of the Remaining Period, the Company will be able to demonstrate and seek its confirmation that Mr. Wu satisfies the requirements under Rule 3.28 of the Listing Rules, having had the benefit of Mr. Chan’s assistance, such that a further waiver will not be necessary.

The Board further announces that Mr. Chan has also been appointed as the agent of the Company for accepting service of process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Listing Rules with effect from 27 April 2021.

The Board would like to take this opportunity to express its gratitude to Dr. Liu for his contribution during his tenure as the joint company secretary and its warm welcome to Mr. Chan of his new appointment.

BIOGRAPHICAL DETAILS OF MR. CHAN SING YUEN, ROY

Mr. Chan Sing Yuen, Roy, aged 55, graduated from the University of Leeds School of Law and the Chinese University of Hong Kong with a bachelor degree of law and a bachelor degree in social science, respectively. Mr. Chan is a practicing solicitor of the High Court of Hong Kong and a practicing solicitor of the Senior Courts of England and Wales. He has extensive experience in the financing and governance of listed companies and is a senior partner of DLA Piper. He is also an arbitrator of the Chinese European Arbitration Centre and the Shanghai International Arbitration Centre.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
27 April 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*